TNK1抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Human fetal brain tissue, Primary antibody: P05434(TNK1 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P05434(TNK1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

**Background of TNK1 Antibody**

The TNK1 (Tyrosine Kinase Non-Receptor 1) gene encodes a non-receptor tyrosine kinase implicated in cellular signaling pathways regulating proliferation, survival, and cytoskeletal dynamics. Discovered in the late 1990s, TNK1 belongs to the ACK (Activated Cdc42-associated kinase) family and contains an SH3 domain, a kinase domain, and a conserved C-terminal region. Unlike many kinases, TNK1 lacks canonical regulatory domains, relying instead on autophosphorylation and interactions with partners like HSP90 or 14-3-3 proteins for activation and stability.

TNK1 antibodies are critical tools for studying its expression, localization, and function. These antibodies are designed to detect TNK1 in techniques such as Western blotting, immunoprecipitation, or immunofluorescence. Research suggests TNK1 is overexpressed in certain cancers, including leukemia and solid tumors, where it may drive oncogenic signaling or chemoresistance. Antibodies help validate TNK1 as a biomarker or therapeutic target.

However, TNK1’s low basal expression in normal tissues and technical challenges in distinguishing it from homologous kinases (e.g., TNK2/ACK1) necessitate highly specific antibodies. Recent studies also link TNK1 to neurodegenerative diseases, expanding its research scope. Commercial TNK1 antibodies are typically polyclonal or monoclonal, validated for selectivity across human and model organisms. Ongoing work aims to clarify TNK1’s dual roles in cancer and neurology, leveraging antibodies to explore its mechanistic and therapeutic potential.